INMB

INmune Bio Inc.

INMB | News | $10.62 4.73% 4.38% 110K

(0.0% 1d) (-10.6% 1m) (52.1% 1y) (0.0% 2d) (4.7% 3d) (19.1% 7d) (-35.88% volume)
Earnings Calendar: 2024-04-01
Market Cap: $ 193,320,034
http://www.inmunebio.com
Sec Filling | Patents | 4 employees

INmune Bio, Inc. focuses on controlling components of the immune system to activate an immune response against cancer and Alzheimer’s disease. Its product pipeline INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer, and LIVNATE. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.

cancer alzheimer alzheimer’s

add to watch list Paper trade email alert is off

Press-releases

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
INMB | News | $10.62 4.73% 4.38% 110K

Health Technology

| 22.49% | O: 19.61% H: 1.74% C: -2.22%
assay for commercial development

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
INMB | News | $10.62 4.73% 4.38% 110K

Health Technology

| 19.06% | O: -2.8% H: 0.0% C: 0.0%
million direct offering

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
INMB | News | $10.62 4.73% 4.38% 110K

Health Technology

| 3.51% | O: 0.97% H: 3.96% C: 0.0%
inb03 breast cancer treatment

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
Published: 2024-03-28 (Crawled : 20:00) - globenewswire.com
INMB | News | $10.62 4.73% 4.38% 110K

Health Technology

| Email alert Add to watchlist
business year update results

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
Published: 2024-03-26 (Crawled : 20:00) - globenewswire.com
INMB | News | $10.62 4.73% 4.38% 110K

Health Technology

| -10.61% | O: -1.18% H: 3.24% C: -0.94%
report update financial results

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
Published: 2024-03-13 (Crawled : 12:00) - globenewswire.com
INMB | News | $10.62 4.73% 4.38% 110K

Health Technology

| -9.69% | O: -1.28% H: 4.13% C: 1.72%
award cell therapy

INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
INMB | News | $10.62 4.73% 4.38% 110K

Health Technology

| -17.42% | O: -0.31% H: 1.64% C: -5.07%
alzheimer’s

INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-12 (Crawled : 14:00) - globenewswire.com
INMB | News | $10.62 4.73% 4.38% 110K

Health Technology

| -12.01% | O: -1.24% H: 5.01% C: 3.94%
conference life sciences

INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
INMB | News | $10.62 4.73% 4.38% 110K

Health Technology

| -10.23% | O: -0.68% H: 7.23% C: 5.53%
biotech series

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
Published: 2024-01-30 (Crawled : 13:00) - globenewswire.com
INMB | News | $10.62 4.73% 4.38% 110K

Health Technology

| -19.36% | O: 2.05% H: 2.46% C: -9.38%
fda disease alzheimer’s program removal

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001213900-24-035474	4	2024-04-23	2024-04-19	Buy	A	18028	18028
0001213900-24-035474	4	2024-04-23	2024-04-19	Buy	A	18028	1538726
0001213900-24-035473	4	2024-04-23	2024-04-19	Buy	A	18028	18028
0001213900-24-035473	4	2024-04-23	2024-04-19	Buy	A	18028	1268179
0001213900-24-035472	4	2024-04-23	2024-04-19	Buy	A	14423	14423
0001213900-24-035472	4	2024-04-23	2024-04-19	Buy	A	14423	1510806
0001213900-24-035471	4	2024-04-23	2024-04-19	Buy	A	29603	29603
0001213900-24-035471	4	2024-04-23	2024-04-19	Buy	A	29603	66603